Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Q3 FY26 investor presentation: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentationreports, not management guidance.
The short version
Q3 FY26 revenue (Income from Operations) was Rs. Quarterly EBITDA: Rs.
From Gujarat Themis Biosyn Ltd's Q3 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Q3 FY26 revenue (Income from Operations) was Rs. 43.37 crore, up 9.74% YoY from Rs. 39.52 crore in Q3 FY25 (Page 6).
- Q3 FY26 PAT was Rs. 12.46 crore, down 3.92% YoY from Rs. 12.97 crore in Q3 FY25 (Page 6).
- Management comment highlights Q3 FY26 top line grew 10% YoY to Rs. 43.4 crore and EBITDA grew 12.9% (Page 4).
- The presentation notes consistency in volumes reflecting healthy demand but does not provide specific volume numbers (Page 4).
2 more points from Gujarat Themis Biosyn Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Gujarat Themis Biosyn Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- New fermentation facility: Completed; production of existing products underway; enables ramp-up in supply capacity (Page 4).
- Expansion of fermentation capacity at current location planned to meet future growth, including organic and inorganic growth in Specialty Chemicals (Page 15).
- New API facility: Recently began commercial operations (Page 15); validation batches for API block completed (Page 4).
- R&D Unit: Commissioned as per international standards for new product development (Page 13).
- Hybrid renewable power project (wind + solar ~18.5 MW) being set up in Gujarat for captive consumption to reduce power costs and carbon footprint (Page 16).
2 more points from Gujarat Themis Biosyn Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gujarat Themis Biosyn Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Gujarat Themis Biosyn Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹44 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gujarat Themis Biosyn Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wanbury Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Ind-Swift Laboratories Ltd (Q3 FY26)
Q2 FY26 Revenue: ₹152.64 Cr (Total Income: ₹170.50 Cr), with a year-on-year (Y-o-Y) increase of 1.91%. Key investor presentation takeaways from Ind-Swift Labora
- Caplin Point Laboratories Ltd (Q3 FY26)
Approximately INR 385 crores has already been spent; the remainder is planned over the next 12 to 18 months. Key concall takeaways from Caplin Point…
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Arthneeti Pro · Annual
Gujarat Themis Biosyn Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gujarat Themis Biosyn Ltd Q3 FY26 results?
Q3 FY26 revenue (Income from Operations) was Rs. Quarterly EBITDA: Rs.
What is Gujarat Themis Biosyn Ltd share price analysis?
Gujarat Themis Biosyn Ltd currently shows a neutral. The stock trades at a P/E of 99.8 with a market cap of ₹4,861 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gujarat Themis Biosyn Ltd planning capital expenditure?
New fermentation facility: Completed; production of existing products underway; enables ramp-up in supply capacity (Page 4).
Keep Gujarat Themis Biosyn Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.